Provided By GlobeNewswire
Last update: Mar 27, 2024
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions
Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis
Read more at globenewswire.comNYSEARCA:MTNB (7/23/2025, 8:04:00 PM)
0.95
0 (-0.02%)
Find more stocks in the Stock Screener